Allogene Therapeutics Enhances Leadership and Affirms Shareholder Decisions

Allogene Therapeutics (ALLO) has issued an announcement.

Allogene Therapeutics, Inc. has appointed Annie Yoshiyama as its new principal accounting officer, bringing with her extensive financial expertise from previous roles at AN2 Therapeutics, Tricida, and Dolby Laboratories. In parallel, the company’s 2024 Annual Meeting witnessed the election of four Class III Directors, approval of executive compensation, and ratification of Ernst & Young LLP as its independent auditor for the year, with significant shareholder participation and support for these agendas.

See more data about ALLO stock on TipRanks’ Stock Analysis page.